Ibrutinib Is Effective in the Treatment of Autoimmune Haemolytic Anaemia in Mantle Cell Lymphoma

Autoimmune haemolytic anaemia (AIHA) in mantle cell lymphoma (MCL) is a rare but life-threatening complication. To date, there are no relevant data for treatment of AIHA in MCL. Ibrutinib, which has been approved for relapse/refractory MCL, is an immunomodulatory drug inhibiting Th2 activation and c...

Full description

Bibliographic Details
Main Authors: Aliénor Galinier, Vincent Delwail, Mathieu Puyade
Format: Article
Language:English
Published: Karger Publishers 2017-01-01
Series:Case Reports in Oncology
Subjects:
Online Access:http://www.karger.com/Article/FullText/456002
id doaj-8bcc771a750f4e519a19da3094eccd6e
record_format Article
spelling doaj-8bcc771a750f4e519a19da3094eccd6e2020-11-24T23:02:07ZengKarger PublishersCase Reports in Oncology1662-65752017-01-0110112712910.1159/000456002456002Ibrutinib Is Effective in the Treatment of Autoimmune Haemolytic Anaemia in Mantle Cell LymphomaAliénor GalinierVincent DelwailMathieu PuyadeAutoimmune haemolytic anaemia (AIHA) in mantle cell lymphoma (MCL) is a rare but life-threatening complication. To date, there are no relevant data for treatment of AIHA in MCL. Ibrutinib, which has been approved for relapse/refractory MCL, is an immunomodulatory drug inhibiting Th2 activation and consequently the production of autoantibodies. We report a case of MCL with AIHA in which this form of anaemia was not controlled with the usual chemotherapy. Ibrutinib was used when MCL with AIHA relapsed, and it allowed rapid remission of AIHA and rapid discontinuation of steroid therapy.http://www.karger.com/Article/FullText/456002Mantle cell lymphomaAutoimmune hemolytic anaemiaIbrutinib
collection DOAJ
language English
format Article
sources DOAJ
author Aliénor Galinier
Vincent Delwail
Mathieu Puyade
spellingShingle Aliénor Galinier
Vincent Delwail
Mathieu Puyade
Ibrutinib Is Effective in the Treatment of Autoimmune Haemolytic Anaemia in Mantle Cell Lymphoma
Case Reports in Oncology
Mantle cell lymphoma
Autoimmune hemolytic anaemia
Ibrutinib
author_facet Aliénor Galinier
Vincent Delwail
Mathieu Puyade
author_sort Aliénor Galinier
title Ibrutinib Is Effective in the Treatment of Autoimmune Haemolytic Anaemia in Mantle Cell Lymphoma
title_short Ibrutinib Is Effective in the Treatment of Autoimmune Haemolytic Anaemia in Mantle Cell Lymphoma
title_full Ibrutinib Is Effective in the Treatment of Autoimmune Haemolytic Anaemia in Mantle Cell Lymphoma
title_fullStr Ibrutinib Is Effective in the Treatment of Autoimmune Haemolytic Anaemia in Mantle Cell Lymphoma
title_full_unstemmed Ibrutinib Is Effective in the Treatment of Autoimmune Haemolytic Anaemia in Mantle Cell Lymphoma
title_sort ibrutinib is effective in the treatment of autoimmune haemolytic anaemia in mantle cell lymphoma
publisher Karger Publishers
series Case Reports in Oncology
issn 1662-6575
publishDate 2017-01-01
description Autoimmune haemolytic anaemia (AIHA) in mantle cell lymphoma (MCL) is a rare but life-threatening complication. To date, there are no relevant data for treatment of AIHA in MCL. Ibrutinib, which has been approved for relapse/refractory MCL, is an immunomodulatory drug inhibiting Th2 activation and consequently the production of autoantibodies. We report a case of MCL with AIHA in which this form of anaemia was not controlled with the usual chemotherapy. Ibrutinib was used when MCL with AIHA relapsed, and it allowed rapid remission of AIHA and rapid discontinuation of steroid therapy.
topic Mantle cell lymphoma
Autoimmune hemolytic anaemia
Ibrutinib
url http://www.karger.com/Article/FullText/456002
work_keys_str_mv AT alienorgalinier ibrutinibiseffectiveinthetreatmentofautoimmunehaemolyticanaemiainmantlecelllymphoma
AT vincentdelwail ibrutinibiseffectiveinthetreatmentofautoimmunehaemolyticanaemiainmantlecelllymphoma
AT mathieupuyade ibrutinibiseffectiveinthetreatmentofautoimmunehaemolyticanaemiainmantlecelllymphoma
_version_ 1725637410407055360